Major strategies for antiviral therapies involve either antibodies which neutralize virus particles, or drugs which target cellular proteins and disrupt the virus life cycle. Protein-protein interactions are involved in each step of the virus cycle, from the viral attachment to the host cell through to its replication.
Homogeneous assays like AlphaLISA®, TR-FRET, or HTRF® are well suited to screening for new protein-protein interaction inhibitors. In this literature review, we have compiled the latest publications about homogeneous assays.
Featured in this review:
- Briefs of several studies dedicated to protein-protein interactions involved in each viral cycle.
- Published data from scientific literature
- How these could lead to an antiviral therapy
